Payment overview · 2025
General Payments
$316.21
12 reported records · 12 companies
Healthcare provider profile · identity verified
Evan M Davidson, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1902245848
Verified facts
What the public records show
CMS Open Payments records show Evan M Davidson, MD received $316.21 in general payments during 2025 across 12 reported records.
Kite Pharma, Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $63.89 | 20.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.73 | 10.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.92 | 8.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.82 | 8.8% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $26.19 | 8.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $25.29 | 8.0% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $22.08 | 7.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.91 | 6.3% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $19.80 | 6.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.53 | 6.2% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $16.14 | 5.1% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.91 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.21 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $63.89 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 85 |
| Losartan Potassium | Losartan Potassium | 291 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 81 |
| Lisinopril | Lisinopril | 234 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 71 |
| Metformin Hcl Er | Metformin Hcl | 167 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 49 |
| Omeprazole | Omeprazole | 149 | 46 |
| Simvastatin | Simvastatin | 126 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 40 |
| Trazodone Hcl | Trazodone Hcl | 114 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 37 |
| Gabapentin | Gabapentin | 106 | 34 |
| Allopurinol | Allopurinol | 105 | 31 |
| Eliquis | Apixaban | 90 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 39 |
| Montelukast Sodium | Montelukast Sodium | 87 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 26 |
| Furosemide | Furosemide | 82 | 31 |
| Metformin Hcl | Metformin Hcl | 82 | 25 |
| Sertraline Hcl | Sertraline Hcl | 77 | 21 |
| Alendronate Sodium | Alendronate Sodium | 76 | 22 |
| Ozempic | Semaglutide | 66 | 12 |
| Ezetimibe | Ezetimibe | 62 | 18 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 12 |
| Meloxicam | Meloxicam | 59 | 23 |
| Carvedilol | Carvedilol | 58 | 18 |
| Benazepril Hcl | Benazepril Hcl | 57 | 15 |
| Famotidine | Famotidine | 54 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | 11 |
| Atenolol | Atenolol | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 13 |
| Potassium Chloride | Potassium Chloride | 42 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 13 |
| Celecoxib | Celecoxib | 39 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 12 |
| Bupropion Xl | Bupropion Hcl | 36 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 15 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Estradiol | Estradiol | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.21 · 12 records | Kite Pharma, Inc. | BRAFTOVI, Cresemba, Enhertu, FOTIVDA, LORBRENA, MEKTOVI, Nubeqa, PYRUKYND, Tibsovo, Trodelvy, VEGZELMA, XT CDX, Xofigo, Yescarta | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error